Literature DB >> 16880766

Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction.

M M Lalu1, J Cena, R Chowdhury, A Lam, R Schulz.   

Abstract

BACKGROUND AND
PURPOSE: The acute vascular inflammatory dysfunction associated with endotoxaemia may reflect an imbalance between matrix metalloproteinases (MMPs) and their natural inhibitors (TIMPs), induced by the endotoxin. This possibility was tested in rat aortic tissue. EXPERIMENTAL APPROACHES: Tone induced by phenylephrine in aortic rings was measured after exposure in vitro to ambient lipopolysaccharide (LPS) or the proinflammatory cytokine interleukin-1beta (IL-1beta) for 6h, with or without MMP inhibitors (doxycycline or GM6001). Gelatinase and MMP activities, TIMP proteins and contractility were measured in aortae taken from rats 6h after receiving LPS in vivo. KEY
RESULTS: Inhibition of MMP prevented the loss of phenylephrine-induced tone in aortic rings after LPS or IL-1beta. IL-1beta also increased release of MMP-2 activity from aortic tissue. In aortae exposed in vivo to LPS, net gelatinase, MMP-9 activities and TIMP-1 protein levels were increased, whereas TIMP-4 was reduced. These aortae were hypocontractile to both phenylephrine and KCl. Hypocontractility was partially reversed by doxycycline ex vivo. CONCLUSIONS AND IMPLICATIONS: MMP inhibitors ameliorate vascular hyporeactivity induced by either LPS or IL-1beta in vitro. LPS in vivo alters the balance between MMPs and TIMPs, contributing to vascular dysfunction which is partially reversed by MMP inhibitors. Vascular MMPs are activated as a result of LPS or IL-1beta-induced stress and contribute to the hyporeactivity of blood vessels to vasoconstrictors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880766      PMCID: PMC1629401          DOI: 10.1038/sj.bjp.0706823

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

1.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

Review 2.  Tissue inhibitors of metalloproteinases: evolution, structure and function.

Authors:  K Brew; D Dinakarpandian; H Nagase
Journal:  Biochim Biophys Acta       Date:  2000-03-07

3.  Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation.

Authors:  T Okamoto; T Akaike; T Sawa; Y Miyamoto; A van der Vliet; H Maeda
Journal:  J Biol Chem       Date:  2001-06-06       Impact factor: 5.157

4.  Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.

Authors:  C Fernandez-Patron; M W Radomski; S T Davidge
Journal:  Circ Res       Date:  1999-11-12       Impact factor: 17.367

5.  Interleukin-1beta, Src- and non-Src tyrosine kinases, and nitric oxide synthase induction in rat aorta in vitro.

Authors:  Y Gui; X L Zheng; M D Hollenberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-08       Impact factor: 4.733

6.  Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice.

Authors:  A Pagenstecher; A K Stalder; C L Kincaid; B Volk; I L Campbell
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

7.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3.

Authors:  G A McQuibban; J H Gong; E M Tam; C A McCulloch; I Clark-Lewis; C M Overall
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

8.  Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock.

Authors:  D D Rees; S Cellek; R M Palmer; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1990-12-14       Impact factor: 3.575

9.  Role of reactive oxygen species in IL-1 beta-stimulated sustained ERK activation and MMP-9 induction.

Authors:  M V Gurjar; J Deleon; R V Sharma; R C Bhalla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-12       Impact factor: 4.733

10.  Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart.

Authors:  P Y Cheung; G Sawicki; M Wozniak; W Wang; M W Radomski; R Schulz
Journal:  Circulation       Date:  2000-04-18       Impact factor: 29.690

View more
  16 in total

Review 1.  Intersection between gonadal function and vascular aging in women.

Authors:  Kerrie L Moreau
Journal:  J Appl Physiol (1985)       Date:  2018-09-13

2.  Resveratrol Prevented Lipopolysaccharide-Induced Endothelial Dysfunction in Rat Thoracic Aorta Through Increased eNOS Expression.

Authors:  Seda Sultan Uğurel; Nilay Kuşçu; Çiler Çelik Özenci; Selvinaz Dalaklıoğlu; Arda Taşatargil
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

3.  Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats.

Authors:  Stephen F Rodrigues; Edward D Tran; Zuleica B Fortes; Geert W Schmid-Schönbein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

Review 4.  Is there new hope for therapeutic matrix metalloproteinase inhibition?

Authors:  Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Nat Rev Drug Discov       Date:  2014-11-07       Impact factor: 84.694

5.  IL-1beta modulate the Ca(2+)-activated big-conductance K channels (BK) via reactive oxygen species in cultured rat aorta smooth muscle cells.

Authors:  Yuan Gao; Ying Yang; Qigang Guan; Xuefeng Pang; Haishan Zhang; Dingyin Zeng
Journal:  Mol Cell Biochem       Date:  2009-12-01       Impact factor: 3.396

6.  Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte.

Authors:  H León; I Baczkó; G Sawicki; P E Light; R Schulz
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

Review 7.  Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature.

Authors:  A K Chow; J Cena; R Schulz
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 8.  Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock.

Authors:  Ineke Vanlaere; Claude Libert
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

9.  Synthesis and Validation of a Hydroxypyrone-Based, Potent, and Specific Matrix Metalloproteinase-12 Inhibitor with Anti-Inflammatory Activity In Vitro and In Vivo.

Authors:  J Aerts; R E Vandenbroucke; R Dera; S Balusu; E Van Wonterghem; L Moons; C Libert; W Dehaen; L Arckens
Journal:  Mediators Inflamm       Date:  2015-08-13       Impact factor: 4.711

Review 10.  Tissue inhibitor of metalloproteinases-4. The road less traveled.

Authors:  Jorge Melendez-Zajgla; Luis Del Pozo; Gisela Ceballos; Vilma Maldonado
Journal:  Mol Cancer       Date:  2008-11-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.